ArticleFrontiers in cellular neuroscience2026
Yellow cerebrospinal fluid in an extremely preterm infant: a case report.
Article in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although phototherapy has reduced the incidence of kernicterus in term infants, it remains a significant threat to extremely preterm infants due to their immature blood-brain barrier and frequent comorbidities such as sepsis. Current clinical practice relies on serum total bilirubin levels, which may not accurately reflect cerebral bilirubin exposure in this vulnerable population. This case report describes an extremely preterm infant (gestational age 28 1/7 weeks, birth weight 950 g) who developed visibly yellow cerebrospinal fluid (CSF) on the first day of life. Despite only minimal serum hyperbilirubinemia (4.4 mg/dL; ≈ 75.2 μmol/L), CSF bilirubin was markedly elevated at 10 mg/dL (≈ 171 μmol/L). The infant presented with respiratory distress syndrome and sepsis. Immediate intensive phototherapy was initiated, leading to the normalization of CSF bilirubin (3.6 mg/dL ≈ 61.5 μmol/L) within 4 days. Brain magnetic resonance imaging (MRI) and automated auditory brainstem response (AABR) performed at the corrected age of 4 months were both unremarkable. At the corrected age of 12 months, neurodevelopmental assessment using the Bayley Scales of Infant Development-III (BSID-III) showed scores within the normal range. This case illustrates that CSF bilirubin can serve as a sensitive early biomarker for identifying preterm infants at imminent risk for bilirubin neurotoxicity, particularly when serum bilirubin levels are misleadingly low. Targeted measurement of CSF bilirubin in selected high-risk infants, when a lumbar puncture is otherwise indicated, could enable more timely intervention and contribute to improved neurodevelopmental outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.